factually
Index/Organizations/Ad26.COV2.S

Ad26.COV2.S

COVID-19 vaccine of Johnson & Johnson

Fact-Checks

3 results
Jan 15, 2026

How do biodistribution results for mRNA (BNT162b2/Moderna) differ from adenoviral (Ad26/ChAdOx1) COVID‑19 vaccines in animal studies?

Animal biodistribution studies of mRNA‑LNP and adenoviral COVID‑19 vaccine platforms show different patterns: preclinical data and regulatory summaries indicate mRNA‑LNP signal concentrates at the int...

Dec 14, 2025

What are current CDC and FDA recommendations for monitoring autoimmune events after the J&J COVID-19 vaccine?

Current CDC and FDA public guidance on COVID-19 vaccination in 2025 focuses on targeted, shared clinical decision‑making for who should receive updated boosters rather than broad, universal campaigns;...

Nov 27, 2025

What are the rates of serious post-vaccine adverse events (myocarditis, VTE, Guillain-Barré) by age, sex, and comorbidity?

Available studies show myocarditis after mRNA COVID-19 vaccines is rare but concentrated in adolescent and young adult males (excess risk up to ~20 per 100,000 doses in some groups), venous thromboemb...